Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients

被引:13
|
作者
Tsai, Kai-Fan [1 ,2 ]
Li, Lung-Chih [1 ,2 ,6 ]
Hsu, Chien-Ning [2 ,3 ,7 ]
Lin, Chih-Che [2 ,4 ]
Lin, Yu-Hung [2 ,4 ]
Cheng, Yu-Fan [2 ,5 ]
Wang, Chih-Chi [2 ,4 ]
Chen, Chao-Long [2 ,4 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Nephrol, 123 Da Pei Rd, Kaohsiung 833, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Pharm, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Ctr, Dept Surg, Kaohsiung, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 59卷 / 03期
关键词
chronic kidney disease; liver transplantation; mTOR inhibitor; renal preservation; urinary biomarkers; CHRONIC KIDNEY-DISEASE; LIPOCALIN NGAL; RAPAMYCIN; TACROLIMUS; EFFICACY; INJURY; STAGE; IMMUNOSUPPRESSION; PROLIFERATION; NEPHROPATHY;
D O I
10.1002/jcph.1334
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mammalian targets of rapamycin inhibitors (mTORIs), including sirolimus and everolimus, are used for minimizing calcineurin inhibitors after liver transplantation. However, head-to-head randomized comparisons of these 2 mTORIs are lacking. We assessed the differences in renoprotection and possible mechanisms between sirolimus and everolimus in liver transplant recipients. For this prospective cohort study, we recruited liver transplant recipients whose regimens were switched from tacrolimus to sirolimus or everolimus at a Taiwan medical center. Serial changes in estimated glomerular filtration rate (eGFR), urinary N-acetyl--D-glucosaminidase, neutrophil gelatinase-associated lipocalin, 8-hydroxy-2-deoxyguanosine, and transforming growth factor-1 during 1 year after mTORI conversion were compared within and between groups. In the 61 patients analyzed, no significant change in eGFR occurred within 12 months after conversion in both mTORI groups. Among patients with baseline eGFR <60 mL/min/1.73 m(2), eGFR improved at 6 months and 1 year after conversion (+12.3 and +12.0 mL/min/1.73 m(2), both P < .05). Urinary N-acetyl--D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +/- 137.6 and -62.0 +/- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +/- 7763.5 ng/g creatinine; P < .05). Neither transforming growth factor-1 nor 8-hydroxy-2 '-deoxyguanosine changed significantly. In conclusion, the renoprotective effect of mTORI conversion was significant in liver transplant recipients with renal insufficiency, which was similar for sirolimus and everolimus, in the first year and may be associated with ameliorated tubular injury. Available evidence remains insufficient to determine which mTORI conversion therapy is more effective in renoprotection in the long run.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [1] Effects of Conversion from Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplantation Recipients
    Li, L-C
    Hsu, C-N
    Lin, C-C
    Cheng, Y-F
    Chen, D-W
    Lee, C-H
    Chen, C-L
    [J]. TRANSPLANTATION, 2017, 101 (05) : 208 - 208
  • [2] Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
    Backman, L
    Reisæter, AV
    Wramner, L
    Ericzon, BG
    Salmela, K
    Brattström, C
    [J]. CLINICAL TRANSPLANTATION, 2006, 20 (03) : 336 - 339
  • [3] Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: Effect on renal function
    Moneim, HA
    Flechner, SM
    Goel, M
    Derweesh, IH
    Modlin, C
    Krishnamurthi, V
    Goldfarb, DA
    Novick, AC
    [J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 419 - 419
  • [4] Conversion of calcineurin inhibitors to sirolimus in liver transplant recipients.
    Mies, Sergio
    Beduschi, Thiago
    Silva, Vinicius M. R.
    Mies, Ana Olga N. G. F.
    Della Guardia, Bianca
    Baia, Carlos E. S.
    de Almeida, Marcio D.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (06) : S189 - S189
  • [5] Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: Effect on renal function.
    Moneim, HA
    Flechner, SM
    George, P
    Derweesh, IH
    Modlin, C
    Krishnamurthi, V
    Goldfarb, D
    Novick, AC
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 376 - 377
  • [6] Conversion from calcineurin inhibitors to sirolimus improves renal function in heart transplant recipients with de novo renal dysfunction
    El-Hamamsy, I.
    Stevens, L. M.
    White, M.
    Perrault, L. P.
    Pellerin, M.
    Carrier, M.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (02): : S120 - S121
  • [7] Conversion from a calcineurin inhibitor to sirolimus in liver transplant recipients with chronic renal insufficiency.
    Dhir, R
    Quinn, MK
    Dennis, V
    Vogt, D
    Henderson, M
    Carey, W
    Levinthal, G
    Barnes, DS
    [J]. HEPATOLOGY, 2002, 36 (04) : 187A - 187A
  • [8] THE EFFECTS OF CONVERSION FROM CNI (CALCINUERIN INHIBITORS) TO SIROLIMUS IN RENAL TRANSPLANT RECIPIENTS
    Borman, Natalie L.
    Venkat-Raman, Gopalakrishnan
    [J]. TRANSPLANT INTERNATIONAL, 2009, 22 : 115 - 115
  • [9] Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors
    Huesing, Anna
    Schmidt, Martina
    Cicinnati, Vito R.
    Koch, Raphael
    Thoelking, Gerold
    Stella, Jaqueline
    Heinzow, Hauke
    Schmidt, Hartmut H.
    Kabar, Iyad
    [J]. ANNALS OF TRANSPLANTATION, 2015, 20
  • [10] Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia
    Fernandez, A.
    Marcen, R.
    Pascual, J.
    Galeano, C.
    Ocana, J.
    Arellano, E. M.
    Alfaro, C.
    Villafruela, J. J.
    Burgos, F. J.
    Ortuno, J.
    [J]. TRANSPLANTATION PROCEEDINGS, 2006, 38 (08) : 2453 - 2455